In animals, specifically DR in its various forms (CR/IF/STS, KD, protein restriction) has shown a potential for simultaneously targeting many of the pathways associated with insulin and IGF signaling, usually with no serious, or with even beneficial side effects such as a differential stress response between normal and tumor tissue
In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79719 and 79725), we created modifier PN to collect data for purposes of implementing section 603 but also to trigger payment under the newly adopted PFS-equivalent rates for nonexcepted items and services
Cell culture studies demonstrate increased expression of synaptic proteins including PSD-95, synaptophysin, and synapsin following Dihexa treatment, confirming molecular mechanisms underlying the observed synaptogenic effects
Preclinical data suggest interactions with dopamine pathways, but human trials remain limited